Heart damage in COVID-19 patients is caused by the novel coronavirus infecting cardiac muscle cells, leading to cell death which interferes with the muscle's contraction, according to a study that may lead to the development of new drugs to treat the viral infection.
WASHINGTON: Heart damage in COVID-19 patients is caused by the novel coronavirus infecting cardiac muscle cells, leading to cell death which interferes
FARAPULSE s Pivotal ADVENT Trial underway with First Patients Treated with its Breakthrough Pulsed Field Ablation System to Treat Atrial Fibrillation
News provided by
Share this article
Share this article
Pioneering technology has demonstrated potential to improve safety for patients with paroxysmal atrial fibrillation and simplify procedures for physicians
MENLO PARK, Calif., March 3, 2021 /PRNewswire/ - FARAPULSE Inc. today announced the first patients were treated in the
ADVENT Trial, a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) pivotal trial to evaluate the safety and effectiveness of its Pulsed Field Ablation (PFA) system for the treatment of paroxysmal Atrial Fibrillation (AF). AF is a heart rhythm disorder that affects nearly 6 million Americans and makes them five times more likely to have a stroke than individuals with a regular heartbeat. The first patients were treated at New York s Mount Sinai Hospital by Dr. Vivek Reddy, the Hel
How coronavirus causes heart damage in Covid-19 patients, shows new study
Novel coronavirus in Covid-19 patients infects cardiac muscle cells, leading to cell death which further interferes with muscle contraction, a new study has found.
advertisement
Representative Image (Photo: Reuters)
Novel coronavirus in Covid-19 patients infects cardiac muscle cells, leading to cell death which further interferes with muscle contraction, a new study has found.
Many studies since the beginning of the pandemic have linked the coronavirus with heart-related problems such as reduced ability to pump blood.
However, now scientists from Washington University School of Medicine in the US say have tried to find out if these are directly caused by the virus infecting the organ, or due to inflammation elsewhere in the body.
First AF Patients Treated With Farapulse Pulsed Field Ablation System
Pioneering technology may simplify procedures and improve outcomes for patients with paroxysmal atrial fibrillation
March 3, 2021 Farapulse Inc. announced the first patients were treated in the ADVENT Trial, a U.S. Food and Drug Administration (FDA) investigational device exemption (IDE) pivotal trial to evaluate the safety and effectiveness of its Pulsed Field Ablation (PFA) system for the treatment of paroxysmal atrial fibrillation (AF).
The first patients were treated at New York s Mount Sinai Hospital by Vivek Reddy, M.D., the Helmsley Trust Professor of Medicine at the Icahn School of Medicine at Mount Sinai and the trial s principal investigator.